Navigation Links
Merck in the Dock Due To Vioxx

The Vioxx case takes a bad turn when the Texas jury awarded $32 million for the family of a 71-year-old man who had died after consuming the painkiller Vioxx. // But this will be greatly reduced by state law. The legal experts say that the verdict is a weak case against Vioxx maker Merck & Co. Inc.

The jury awarded Leonel Garza's family $7 million in compensatory damages for mental anguish and personal loss and $25 million in punitive damages, but the latter will be cut to no more than $750,000 because of a cap imposed by Texas law. Merck immediately said it would appeal the decision. It withdrew the $2.5 billion-a-year drug after it found that the use of Vioxx for more than 18 months doubled the risk of stroke and heart attack. Attorneys for Garza's family said that Vioxx caused blood clots that led to a fatal heart attack. They said Merck lied when it said only long-term use of Vioxx presented health dangers and accused the company of keeping the drug on the market long after learning of its risks because the New Jersey-based company needed the sales.

This led to the discovery that short-term use of Vioxx as a causative of heart attacks. Merck lawyers blamed Garza's death on heart disease that had plagued him since 1978. Merck attorney Richard Josephson said medical records indicate he may have taken Vioxx for only a week and stopped the medicine nearly three weeks before his death which shows that Vioxx was not involved in any way in Leonel Garza's death. But Kenneth Frazier, senior vice president and general counsel, told a conference call after the verdict that the company would fight each case and settle none.

Merck last year spent $285 million on legal fees related to Vioxx, and said its reserve fund for future litigation stood at $685 million at the end of 2005. Wall Street is watching the Vioxx trials closely for clues about how much the Vioxx issue ultimately will cost Merck. Shares of Merck closed down 26 cents at $34.74 on the New York Stock Exchange.


Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab
4. Judgment In Favor Of Merck For Vioxx Drug
5. Merck, ICMR to conduct joint trials on cervical cancer vaccine
6. Merck Says Januvia Effective In Type 2 Diabetes
7. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
8. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
9. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
10. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
11. Ranbaxy in Fray to Buy Mercks Generic Drugs Unit
Post Your Comments:

(Date:11/25/2015)... , ... November 25, 2015 , ... ... where preparing the perfect dish and pleasing the palates of attendees is of ... bringing a dish to a seasonal get-together, give these recipes a try this ...
(Date:11/25/2015)... NV (PRWEB) , ... November 25, 2015 , ... Dr. ... patients to learn more about hair loss treatment with the Capillus272™ Pro laser therapy ... effective solution for thicker and fuller hair, without the need for surgery, prescription pills, ...
(Date:11/25/2015)... ... , ... According to an article published November 10th by The ... as a breakthrough for performing hernia repairs. The article explains that the biggest advantage ... it can greatly reduce the pain that a patient might otherwise experience after a ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for physicians and athletic programs, launches new Wimbledon Athletics Facebook page ... testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age ...
(Date:11/25/2015)... ... 25, 2015 , ... SCOTTSDALE, AZ) - Today, Dr. ... both surgical and non-surgical treatments, announced the expansion of his private practice capabilities ... , Highly trained and nationally recognized for his natural approach, Dr. Todd ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the Global Cell Surface Testing Market: ... report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
Breaking Medicine Technology: